Cosmin Cojocaru

Dr. Cosmin Cojocaru

Carol Davila University of Medicine and Pharmacy Bucharest
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
AZAlexandru Zlibut
Alexandru Zlibut
Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
Sebastian OnciulSebastian Onciul
Sebastian Onciul
LALucia Agoston-Coldea
Lucia Agoston-Coldea
Subclinical alterations in myocardial structure and function occur early during the natural disease course. In contrast, clinically overt signs and symptoms occur during late phases, being associated with worse outcomes. Identification of such subclinical changes is critical for timely diagnosis and accurate management. Hence, implementing cost-effective imaging techniques with accuracy and reproducibility may improve long-term prognosis. A growing body of evidence supports using cardiac magnetic resonance (CMR) to quantify deformation parameters. Tissue-tagging (TT-CMR) and feature-tracking CMR (FT-CMR) can measure longitudinal, circumferential, and radial strains and recent research emphasize their diagnostic and prognostic roles in ischemic heart disease and primary myocardial illnesses. Additionally, these methods can accurately determine LV wringing and functional dynamic geometry parameters, such as LV torsion, twist/untwist, LV sphericity index, and long-axis strain, and several studies have proved their utility in prognostic prediction in various cardiovascular patients. More recently, few yet important studies have suggested the superiority of fast strain-encoded imaging CMR-derived myocardial strain in terms of accuracy and significantly reduced acquisition time, however, more studies need to be carried out to establish its clinical impact. Herein, the current review aims to provide an overview of currently available data regarding the role of CMR in evaluating myocardial strain and biomechanics.

9 May 2023 in Journal Of Hypertension
Verified
Journal Article
Closed access
MDMaria Dorobantu
Maria Dorobantu
Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
LSLaura Adina Stanciulescu
Laura Adina Stanciulescu
CPCalin Pop
Calin Pop
CBCornelia Bala
Cornelia Bala
OGOana-Florentina Gheorghe-Fronea
Oana-Florentina Gheorghe-Fronea
Objectives: This national representative survey sought to assess hypertension's prevalence, awareness, treatment and control in Romania. Methods: A representative sample (by age, sex and residence) of 1477 Romanian adults (51.19 ± 16.61 years, range 18–80 years, 59.9% women) was multimodally evaluated during two study visits. Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg or previously diagnosed hypertension, regardless of BP. Awareness was defined by knowledge of previous hypertension diagnosis or of current use of antihypertensive treatment. Treatment was defined by antihypertensive medication taken at least 2 weeks prior to enrolment. Control was defined as SBP less than 140 mmHg and DBP less than 90 mmHg at both visits in treated hypertensive patients. Results: Hypertension prevalence was 46% (n = 680) consisting of 81.02% (n = 551) known hypertensive patients and 18.98% (n = 129) newly diagnosed hypertensive patients. Awareness, treatment and control of hypertension were: 81% (n = 551), 83.8% (n = 462) and 39.2% (n = 181). Conclusion: Despite numerous pandemic-related obstacles in conducting a national survey, SEPHAR IV updates hypertension epidemiological data of a high-cardiovascular-risk Eastern-European population. This study confirms previous predictions of hypertension prevalence, treatment and control, which remain unfavourable because of unsatisfactory control of promoting factors.

12 September 2021 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
DPD. Penela
D. Penela
ABAntonio Berruezo
Antonio Berruezo
RVR. Vatasescu
R. Vatasescu

26 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DRDan-Andrei Radu
Dan-Andrei Radu
Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
Sebastian OnciulSebastian Onciul
Sebastian Onciul
ASAlina Scarlatescu
Alina Scarlatescu
AZAlexandru Zlibut
Alexandru Zlibut
MDMaria Dorobantu
Maria Dorobantu
Hypertrophic cardiomyopathy (HCM) is an inherited primary myocardial disease characterized by asymmetrical/symmetrical left ventricle (LV) hypertrophy, with or without LV outflow tract (LVOT) dynamic obstruction, and poor prognosis. Cardiac resynchronization therapy (CRT) has emerged as a minimally invasive tool for patients with heart failure (HF) with decreased LV ejection fraction (LVEF) and prolonged QRS duration of over 120 ms with or without left bundle branch block (LBBB). Several HCM patients are at risk of developing LBBB because of disease progression or secondary to septal myomectomy, while others might develop HF with decreased LVEF, alleged end-stage/dilated HCM, especially those with thin myofilament mutations. Several studies have shown that patients with myectomy-induced LBBB might benefit from left bundle branch pacing or CRT to relieve symptoms, improve exercise capacity, and increase LVEF. Otherwise, patients with end-stage/dilated HCM and prolonged QRS interval could gain from CRT in terms of NYHA class improvement, LV systolic performance increase and, to some degree, LV reverse remodeling. Moreover, several electrical and imaging parameters might aid proper selection and stratification of HCM patients to benefit from CRT. Nonetheless, current available data are scarce and further studies are still required to accurately clarify the view. This review reassesses the importance of CRT in patients with HCM based on current research by contrasting and contextualizing data from various published studies.

Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
AVAura-Elena Vîjîiac
Aura-Elena Vîjîiac
OGOana Gheorghe-Fronea
Oana Gheorghe-Fronea
TMTeodora Mohaiu
Teodora Mohaiu
LILucian Mihai Itu
Lucian Mihai Itu
Maria DorobantuMaria Dorobantu
Maria Dorobantu
Objectives: There are limited epidemiological data regarding atrial fibrillation (AF) in hypertensive (HT) Romanian adults. We sought to evaluate AF prevalence trends in the SEPHAR surveys (Study for Evaluation of Prevalence of Hypertension and Cardiovascular Risk in an Adult Population in Romania) during a nine-year interval (2012–2016–2021). Methods: Three consecutive editions of a national epidemiological survey regarding HT included representative samples of subjects stratified by age, gender and area of residence (SEPHAR II-IV—in total, 5422 subjects, mean age 48.69 ± 16.65 years, 57.5% (n = 3116) females). A post-hoc analysis of AF prevalence and oral anticoagulation (OAC) rates was performed. AF definition was based on a documented medical history of AF and/or AF documentation by study electrocardiogram. Results: General AF prevalence was 5.5% (n = 297). AF prevalence in HT subjects was 8.9% (n = 209) and has risen since SEPHAR II—7.2% (n = 57) and SEPHAR III—8.1% (n = 72) to SEPHAR IV—11.8% (n = 80), respectively (p = 0.001). AF prevalence has increased in HT males (SEPHAR II—5.3% (n = 19), SEPHAR III—7.6% (n = 26) and SEPHAR IV—11.7% (n = 35) (p = 0.010)) and in HT from urban areas (SEPHAR II—7.8% (n = 37), SEPHAR III—7.8% (n = 40), SEPHAR IV—14.7% (n = 50), p < 0.001). In SEPHAR III-IV, only 19.3% (n = 23) of HT AF patients with OAC indication were anticoagulated. Conclusions: AF prevalence has increased by ~64% in hypertensive Romanian adults between 2012 and 2021. However, anticoagulation strategies may be suboptimal in patients with cardioembolic risk.

Verified
Journal Article
Open access
PDF file
PNPopa- Fotea Nicoleta-Monica
Popa- Fotea Nicoleta-Monica
Cosmin CojocaruCosmin Cojocaru
Cosmin Cojocaru
ASAlexandru Scafa-Udriste
Alexandru Scafa-Udriste
MMMiruna Micheu
Miruna Micheu
Maria DorobantuMaria Dorobantu
Maria Dorobantu
Pediatric inherited cardiomyopathies (CMPs) and channelopathies (CNPs) remain important causes of death in this population, therefore, there is a need for prompt diagnosis and tailored treatment. Conventional evaluation fails to establish the diagnosis of pediatric CMPs and CNPs in a significant proportion, prompting further, more complex testing to make a diagnosis that could influence the implementation of lifesaving strategies. Genetic testing in CMPs and CNPs may help unveil the underlying cause, but needs to be carried out with caution given the lack of uniform recommendations in guidelines about the precise time to start the genetic evaluation or the type of targeted testing or whole-genome sequencing. A very diverse etiology and the scarce number of randomized studies of pediatric CMPs and CNPs make genetic testing of these maladies far more particular than their adult counterpart. The genetic diagnosis is even more puzzling if the psychological impact point of view is taken into account. This review aims to put together different perspectives, state-of-the art recommendations—synthetizing the major indications from European and American guidelines—and psychosocial outlooks to construct a comprehensive genetic assessment of pediatric CMPs and CNPs.